Dr. Michael Har-Noy Discusses The Rationale Behind His Ground-Breaking CRCL-AlloVaxTM Treatment

4 Mar

Dr. Michael Har-Noy, CEO of the Israeli biotechnology company Immunovative Therapies Ltd., says that the CRCL-AlloVax™ anti-tumor vaccine is an immunologic treatment that has been designed based upon scientific principle and extensive research.  The potential benefit of this therapeutic vaccine has been previously demonstrated in extensive pre-clinical work and in early clinical trials.  Dr. Michael Har-Noy is currently conducting a Phase I/II study of CRCL-AlloVax™ in Bangkok, Thailand.  This study is part of a comprehensive Compassionate Use program.

It is well recognized, says Dr. Michael Har-Noy, that prior approaches to treating cancer with immunotherapy have demonstrated very limited efficacy.  CRCL-AlloVax™ represents an anti-tumor vaccine designed specifically with these previous failures in mind.  In developing CRCL-AlloVaxTM, Dr. Michael Har-Noy specifically considered the obstacles which have hindered the clinical efficacy of prior immunotherapy approaches and took measures to circumvent them.

Dr. Michael Har-Noy describes CRCL-AlloVaxTM as a vaccine engineered to elicit a response similar to the already proven and often curative tumor killing mechanism of an allogeneic bone marrow transplant.  Unfortunately, the allogeneic bone marrow transplant is frequently associated with the lethal side effect of graft-versus-host disease (GVHD).  The CRCL-AlloVax™ vaccine, says Dr. Michael Har-Noy, is designed to preserve the proven beneficial anti-tumor effect of a bone marrow transplant while eliminating the devastating GVHD side-effect.

The beneficial anti-tumor effect of an allogeneic bone marrow transplant, says Dr. Michael Har-Noy, has been shown to eradicate significant solid tumor burdens in patients with chemotherapy-resistant metastases. However, this phenomenon has no practical large-scale application due to the GVHD side effect.   Dr. Michael Har-Noy believes that the capacity of CRCL-AlloVax™ to provide patients with a proven anti-tumor immune effect without risk of GVHD is a landmark break-through in immunotherapy drug design.  The powerful scientific theory behind CRCL-AlloVaxTM and the early promising clinical results provides the rationale for this experimental compound to be available to metastatic cancer patients for early access.

Dr. Michael Har-Noy is currently running a preliminary Phase I/II study of CRCL-AlloVaxTM in patients with various types of chemotherapy and radiation-resistant metastatic cancer.  This study is part of a broad Compassionate Use program in Bangkok, Thailand.  For more information, please visit www.immunocare.net


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: